| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/BBRC.1994.1742 |
| P698 | PubMed publication ID | 8002990 |
| P2093 | author name string | Kaur G | |
| Carlson BA | |||
| Sausville EA | |||
| Worland PJ | |||
| Losiewicz MD | |||
| P433 | issue | 2 | |
| P921 | main subject | alvocidib hydrochloride | Q27163006 |
| alvocidib | Q4063441 | ||
| P304 | page(s) | 589-595 | |
| P577 | publication date | 1994-06-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. | |
| P478 | volume | 201 |
| Q42536068 | 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors |
| Q41808100 | A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity. |
| Q34214083 | A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol |
| Q36534059 | A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. |
| Q46566761 | A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study |
| Q40219887 | A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo |
| Q24300982 | A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B |
| Q41954708 | An unmet actin requirement explains the mitotic inhibition of clathrin-mediated endocytosis. |
| Q39703056 | Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancer. |
| Q43919047 | Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases |
| Q40188770 | Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest |
| Q34803868 | B-chronic lymphocytic leukemia: practical aspects |
| Q31407508 | Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. |
| Q99551088 | CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells |
| Q73419649 | Caspase-2 mediates neuronal cell death induced by beta-amyloid |
| Q28077520 | Centrosome - a promising anti-cancer target |
| Q42063008 | Chemical inhibitors of cyclin-dependent kinases |
| Q44602400 | Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion |
| Q41906775 | Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. |
| Q27631578 | Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein |
| Q28137611 | Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases |
| Q44323443 | Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. |
| Q34075028 | Cyclin-dependent kinase inhibitors: novel anticancer agents |
| Q37445826 | Cyclin-dependent kinases as a therapeutic target for stroke. |
| Q35038779 | Cyclin-dependent kinases as new targets for the prevention and treatment of cancer |
| Q80510509 | Cyclin-dependent kinases as targets for cancer therapy |
| Q81086253 | Cyclin-dependent kinases as targets for cancer therapy |
| Q77744421 | Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure |
| Q33264498 | Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues. |
| Q36825077 | Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule |
| Q32173424 | Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies |
| Q33859300 | Discovering novel chemotherapeutic drugs for the third millennium |
| Q35669507 | Discovery of small molecule inhibitors of xyloglucan endotransglucosylase (XET) activity by high-throughput screening |
| Q53674064 | Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science. |
| Q44158321 | Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations |
| Q28365275 | Effect of P-glycoprotein on flavopiridol sensitivity |
| Q44650227 | Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells |
| Q40815132 | Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21(waf/cip1), p27(kip1), and Cdc25C expression |
| Q43588630 | Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. |
| Q37447008 | Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells |
| Q36019515 | Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia |
| Q30439662 | Fine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit |
| Q36716750 | Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs |
| Q34082542 | Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo |
| Q40614766 | Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. |
| Q33910799 | Flavopiridol inhibits P-TEFb and blocks HIV-1 replication |
| Q27625712 | Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site |
| Q34752291 | Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances ap |
| Q34615632 | Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development |
| Q28369193 | Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis |
| Q34090992 | Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status |
| Q33832656 | Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials |
| Q36379379 | From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. |
| Q74303819 | G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells |
| Q73009429 | G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis |
| Q92860899 | Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells |
| Q41680336 | Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein |
| Q37141676 | Incorporation of biologic therapies in the management of gastroesophageal cancers |
| Q73484107 | Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin |
| Q39475375 | Inhibition of cyclin-dependent kinase activity and induction of apoptosis by preussin in human tumor cells |
| Q27734755 | Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine |
| Q27621242 | Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent |
| Q40433984 | Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs |
| Q31098941 | Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity |
| Q30883163 | Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. |
| Q38068978 | Investigational cell cycle inhibitors in clinical trials for bladder cancer |
| Q38949247 | Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016). |
| Q33178580 | Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death |
| Q34840838 | Isoflavones for prevention of cancer, cardiovascular diseases, gynecological problems and possible immune potentiation |
| Q58992689 | Linear and Nonlinear QSAR Study of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 Inhibitors |
| Q38888994 | Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer |
| Q44352638 | Mechanism of H-8 inhibition of cyclin-dependent kinase 9: study using inhibitor-immobilized matrices |
| Q34224865 | Mechanisms of action of flavopiridol |
| Q74586597 | Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver |
| Q41093461 | Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein |
| Q37962816 | Molecular targeted agents for gastric and gastroesophageal junction cancer |
| Q40545634 | Moscatilin from the orchid Dendrobrium loddigesii is a potential anticancer agent |
| Q74070484 | Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress |
| Q64265730 | Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy |
| Q38888042 | Natural Products as Mechanism-based Anticancer Agents: Sp Transcription Factors as Targets |
| Q34441101 | Natural products in anticancer therapy. |
| Q34348290 | New agents for prostate cancer |
| Q37855812 | Novel potent pharmacological cyclin-dependent kinase inhibitors |
| Q30613304 | Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. |
| Q33952759 | Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias |
| Q33671881 | Phytoestrogens and inhibition of angiogenesis. |
| Q40927437 | Potent interaction of flavopiridol with MRP1 |
| Q38988581 | Potential Use of Flavopiridol in Treatment of Chronic Diseases |
| Q73964524 | Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression |
| Q93006056 | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
| Q40118604 | Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178. |
| Q48094020 | Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. |
| Q24562983 | Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors |
| Q34293568 | Small molecule modulators of cyclin-dependent kinases for cancer therapy |
| Q35551149 | Small-molecule cyclin-dependent kinase modulators |
| Q37672900 | Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. |
| Q55036064 | Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA. |
| Q43503842 | Structure-activity relationship studies of flavopiridol analogues |
| Q26827580 | Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors |
| Q41099705 | Targeting signal transduction for disease therapy |
| Q41611829 | Targeting signal transduction for disease therapy |
| Q39662628 | Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen |
| Q37923861 | The CDK inhibitors in cancer research and therapy. |
| Q43569842 | The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. |
| Q35157537 | The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer |
| Q54977960 | The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. |
| Q33871868 | The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity |
| Q42122796 | The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. |
| Q30445825 | The reversibility of mitotic exit in vertebrate cells |
| Q36181206 | The therapeutic potential of targeting the cell cycle |
| Q35091146 | The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy |
| Q38161381 | Transcription inhibition as a therapeutic target for cancer |
| Q39883712 | Transforming growth factor-{beta}-inducible phosphorylation of Smad3 |
| Q35214727 | Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis |
| Q30847612 | p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol |
Search more.